Serum Irisin Levels in Patients with Acute Atrial Fibrillation

Objective. The purpose of this research was to investigate whether changes in serum irisin levels can represent a marker of al-tered energy requirements in patients with acute atrial fibrillation (AF) undergoing cardioversion (CV).

Methods. The research was planned as a randomized, prospective case-control study. Patients presenting to the emer-gency medicine and cardiology depart-ments of a university hospital due to acute AF were included in the study. Irisin levels were measured from serum specimens col-lected 24 and 72 hours (h) following resto-ration of sinus rhythm with CV in patients in AF rhythm. The values obtained were then compared using statistical analysis. Results. Thirty-one patients undergoing CV due to acute AF were enrolled. Mean irisin levels were studied from serum spec-imens collected 24 and 72 h following res-toration of sinus rhythm with CV, and were then compared. No statistically significant difference was determined at comparison of patients’ basal to 24 h, basal to 72 h, and 24 to 72 h mean irisin values (p=0.734, p=0.958, and p=0.643, respectively). Nega-tive correlation was determined between basal serum irisin levels and LDL (r=-0.519, p=0.002), but no significant correla-tion was observed with epicardial adipose tissue (EAT) thickness.

Conclusion. We determined no change in serum irisin levels studied 24 h and 72 h following return of normal sinus rhythm after CV from basal serum irisin levels in patients with acute AF. No correlation also was determined between serum irisin lev-els and EAT thickness.

Atrial fibrillation, Irisin, Epicar-dial adipose tissue, Cardioversion

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016;50(5):e1-e88.

2. Barbey O, Pierre S, Duran MJ, Sennoune S, Levy S, Maixent JM. Specific up-regulation of mitochondrial F0F1-ATPase activity after short episodes of atrial fibrillation in sheep. J Cardiovasc Electrophysiol 2000 ;11(4):432-8.

3. White CW, Kerber RE, Weiss HR, Marcus ML. The effects of atrial fibrillation on atrial pressure-volume and flow relationships. Circ Res 1982 ;51(2):205-15

4. Ausma J, Coumans WA, Duimel H, Van der Vusse GJ, Allessie MA, Borgers. Atrial high energy phosphate content and mitochon-drial enzyme activity during chronic atrial fibrillation. Cardiovasc Res 2000;47(4):788-96

5. Leistad E, Aksnes G, Verburg E, Christensen G. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by vera-pamil but increased by BAY K8644. Circulation 1996;93(9):1747-54

6. Cha YM, Dzeja PP, Shen WK, Jahangir A, Hart CY, Terzic A, et al. Failing atrial myocardium: energetic deficits accompany structural remodeling and electrical instability. Am J Physiol Heart Circ Physiol 2003;284(4):H1313-20.

7. Seppet E, Eimre M, Peet N, Paju K, Orlova E, Ress M, et al. Compartmentation of energy metabolism in atrial myocardium of pa-tients undergoing cardiac surgery. Mol Cell Biochem.2005; 270(1-2):49-61

8. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104(2):174-80.

9. Tsuboi M, Hisatome I, Morisaki T, Tanaka M, Tomikura Y, Takeda S, et al. Mitochondrial DNA deletion associated with the reduction of adenine nucleotides in human atrium and atrial fibrillation. Eur J Clin Invest 2001;31(6):489-96.

10. Aydin S. Three new players in energy regulation: preptin, adropin and irisin. Peptides. 2014;56:94-110.

11. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like devel-opment of white fat and thermogenesis. Nature 2012;481(7382):463-8.

12. Kuloglu T, Aydin S, Eren MN, Yilmaz M, Sahin I, Kalayci M, et al. Irisin: a potentially candidate marker for myocardial infarction. Peptides 2014;55:85-91.

13. Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit Rev Clin Lab Sci 2015;52:180-90.

14. Shin SY, Yong HS, Lim HE, Na JO, Choi CU, Choi JI, et al. Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2011;22:647–655

15. Tsao HM, Hu WC, Wu MH, Tai CT, Lin YJ, Chang SL, et al. Quantitative analysis of quantity and distribution of epicardial ad-ipose tissue surrounding the left atrium in patients with atrial fibrillation and effect of recurrence after ablation. Am J Cardiol 2011;107:1498–1503.

16. Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 2014;102(2):205-13.

17. Aydin S, Aydin S, Kobat MA, Kalayci M, Eren MN, Yilmaz M, et al. Decreased saliva/serum irisin concentrations in the acute myo-cardial infarction promising for being a new candidate biomarker for diagnosis of this pathology. Peptides 2014;56:141-5.

18. Sahin M, Canpolat AG, Corapcioglu D, Canpolat U, Emral R, Uysal AR. Association between circulating irisin levels and epicardial fat in patients with treatment-naïve overt hyperthyroidism. Biomarkers 2018 ;25:1-6.

19. Kaneda H, Nakajima T, Haruyama A, Shibasaki I, Hasegawa T, Sawaguchi T, et al. Association of serum concentrations of irisin and theadipokines adiponectin and leptin with epicardial fat in cardiovascular surgery patients. PLoS One. 2018;13(8):e0201499

20. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – correlation with body mass index. Peptides 2013;39:125–30

21. Moreno-Navarette JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, et al. Irisin is expressed and produced by human mus-cle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013;98:E769–78.

22. Liu JJ, Wong MD, Toy WC. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013;27:365–69